by Kelley Tracy | Apr 27, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it is Licensing to Basilea Pharmaceutica, Ltd. a Broad Spectrum Anti-Fungal Platform Technology Doylestown, PA. April 27, 2022 – FCCDC is pleased to announce that FCCDC is licensing to Basilea Pharmaceutica, Ltd....
by Kelley Tracy | Jun 25, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded an NIH Grant from the National Institution of Aging Entitled “Therapeutics Targeting TDP-43 to Treat Alzheimer’s Disease and Related Disorders” Doylestown, PA. June 25, 2021...
by Kelley Tracy | Apr 20, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled “Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum” Doylestown, PA. April 20, 2021...
by Kelley Tracy | Mar 3, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant Entitled “Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Virus” Doylestown, PA. March 3, 2021 – FCCDC is pleased to announce that...
by Kelley Tracy | Jul 17, 2020 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle” Doylestown, PA. July 17, 2020 – FCCDC is pleased to announce...
